UNSPSC 51172813: Benzocaine/phenol

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR900. This VA Drug Class (OR900) classifies this compound as belonging to the group DENTAL AND ORAL AGENTS, TOPICAL, OTHER.

UNSPSC 51172813 Benzocaine/phenol, a Commodity code, encompasses topical anesthetic and antimicrobial pharmaceutical products that state and local health agencies procure through cooperative purchasing vehicles and direct solicitations. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, exemplifies the buying activity under this code: MMCAP issued an RFP in January 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon. State and local health departments, corrections systems, and other government-operated medical facilities are the primary end users, sourcing these products through authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) rather than direct from manufacturers. Vendors responding to this code must comply with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain contractual relationships with at least two of the three designated wholesalers, and carry commercial general liability insurance of $5 million per occurrence and professional liability coverage of $2 million.

The geographic activity centers on the upper Midwest and Pacific Northwest based on MMCAP's membership footprint spanning Minnesota and Oregon. The representative opportunity—MMCAP's RFP for generic multi-source pharmaceuticals and OTC products with proposals due March 26, 2026—shows evaluation weighted heavily toward price competitiveness (75 percent), with smaller weight on fixed pricing, administrative compliance, EDI capability, and administrative fee acceptance (5–10 percent each). The contract structure runs two years for new vendors and extends to June 30, 2028 for incumbents, with MMCAP reserving multi-award authority based on therapeutic considerations and member-specific needs. No specific set-aside designations or dollar values appear in the solicitation documentation; performance penalties range from $200 to $1,500 per violation for late reporting, missed onboarding, or improper class-of-trade denials. All products must achieve FDA compliance, possess expiration dates of at least one year from manufacture, and be available in the marketplace by May 15, 2026.